|1.||Marcucci, Guido: 6 articles (06/2015 - 06/2006)|
|2.||Chan, Kenneth K: 5 articles (06/2015 - 06/2006)|
|3.||Liu, Shujun: 4 articles (06/2015 - 06/2008)|
|4.||Xie, Zhiliang: 4 articles (06/2014 - 06/2008)|
|5.||Zwiebel, James A: 4 articles (06/2014 - 06/2008)|
|6.||Blum, William: 4 articles (06/2014 - 06/2006)|
|7.||Liu, Zhongfa: 4 articles (06/2014 - 06/2006)|
|8.||Vassilakos, Aikaterini: 4 articles (07/2011 - 06/2003)|
|9.||Yen, Yun: 4 articles (04/2011 - 05/2006)|
|10.||Byrd, John C: 3 articles (06/2015 - 06/2008)|
|1.||Prostatic Neoplasms (Prostate Cancer)
04/01/2011 - "A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer."
04/01/2011 - "This phase II trial was conducted to determine the efficacy and tolerability of GTI-2040 when combined with docetaxel and prednisone for the treatment of patients with castration-resistant prostate cancer (CRPC). "
06/01/2003 - "Taken together, the results of these studies indicate that GTI-2040 can act as a selective and specific anticancer agent against a broad range of human tumors."
01/01/2009 - "In combination with GTI-2040 there were cooperative effects at intermediate doses of the two agents and complete tumor regression at higher combination doses. "
10/01/2001 - "GTI-2040 has been tested in nine different tumor models, including tumors derived from colon, liver, lung, breast, kidney and ovary. "
06/01/2005 - "A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors."
07/01/2011 - "GTI-2040 has been shown to inhibit human cancer cell proliferation by downregulation of R2 expression in vitro and to significantly inhibit tumor growth in xenograft models of human cancer in mice. "
|3.||Renal Cell Carcinoma (Grawitz Tumor)
04/01/2008 - "A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma."
10/01/2001 - "By August 2001, GTI-2040 was undergoing a phase II trial as a monotherapy for the potential treatment of renal cell carcinoma, and was about to enter a phase II combination study for this indication with capecitabine (Hoffmann-La Roche). "
01/01/2009 - "In the present study, the anti-tumor activity of GTI-2040, in combination with interferon alpha (IFNalpha) was investigated against human renal cell carcinoma tumors xenografted into mice. "
|4.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
06/01/2014 - "In a phase I dose escalation trial, adults (≥ 60 years) with refractory or relapsed acute myeloid leukemia (AML) received daily HiDAC plus infusional GTI-2040. "
06/01/2015 - "CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia."
06/01/2006 - "The utility of this assay was demonstrated by simultaneous determination of GTI-2040 in plasma and its intracellular levels in treated acute myeloid leukemia patients. "
06/15/2008 - "We performed a phase I dose escalation trial of AraC combined with GTI-2040, a 20-mer antisense oligonucleotide shown in preclinical studies to decrease levels of the R2 subunit of ribonucleotide reductase, to determine the maximum tolerated dose in adults with relapsed/refractory acute myeloid leukemia. "
06/01/2015 - "CD33-targeted lipid nanoparticles (aCD33LNs) were synthesized for delivery of GTI-2040, an antisense oligonucleotide (ASO) against the R2 subunit of ribonucleotide reductase, to acute myelogenous leukemia (AML). "
06/01/2003 - "In addition to tumor growth assays, GTI-2040 was tested in a murine model of human lymphoma. "
06/01/2005 - "This study of GTI-2040, a 20-mer phosphorothioate oligonucleotide complementary to the messenger ribonucleic acid (mRNA) of the R2 subunit of ribonucleotide reductase (RNR), was conducted to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of the agent in patients with advanced solid tumors or lymphoma. "
|3.||Ribonucleotide Reductases (Ribonucleotide Reductase)
|6.||Messenger RNA (mRNA)
|7.||Interferon-alpha (Interferon Alfa)
|8.||RNA (Ribonucleic Acid)
|10.||ribonucleotide reductase M2
|3.||Heterologous Transplantation (Xenotransplantation)
|5.||Drug Therapy (Chemotherapy)